Is Boston Scientific Corp. (BSX) Positioned for Solid, Durable Growth?

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 Index surged in the third quarter, driven by investor optimism that grew on expectations of monetary easing, strong consumer demand, and solid corporate earnings. The Fund (Investor Shares) returned 2.57% (net of fees) in the quarter, trailing the S&P 500 Index’s 8.12% return. YTD, the fund returned 9.89% compared to 14.83% for the index. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its third-quarter 2025 investor letter, Parnassus Core Equity Fund highlighted stocks such as Boston Scientific Corporation (NYSE:BSX). Boston Scientific Corporation (NYSE:BSX) manufactures and markets medical devices that operate in the MedSurg and Cardiovascular segments. The one-month return of Boston Scientific Corporation (NYSE:BSX) was -4.86%, and its shares gained 5.89% of their value over the last 52 weeks. On December 22, 2025, Boston Scientific Corporation (NYSE:BSX) stock closed at $96.43 per share, with a market capitalization of $142.952 billion.

Parnassus Core Equity Fund stated the following regarding Boston Scientific Corporation (NYSE:BSX) in its third quarter 2025 investor letter:

"We made only a few substantial moves in the quarter. In the Health Care sector, we trimmed Eli Lilly and Stryker, using the proceeds to initiate a position in Boston Scientific Corporation (NYSE:BSX), an innovative medical device maker with significant growth drivers. Boston Scientific’s first-mover advantage, robust clinical data and deep relationships with physicians allow it to maintain dominant market share and outgrow competitors, with additional growth drivers like Watchman and Farapulseto help it expand rapidly in underpenetrated markets. Management, led by CEO Mike Mahoney, has transformed the company through disciplined R&D and M&A, driving organic sales growth and margin expansion. With consistent execution, expanding margins and global demand tailwinds, Boston Scientific is well positioned for durable growth."

Boston Scientific Corporation (NYSE:BSX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 102 hedge fund portfolios held Boston Scientific Corporation (NYSE:BSX) at the end of the third quarter, compared to 100 in the previous quarter. Boston Scientific Corporation (NYSE:BSX) announced that its consolidated revenue for the third quarter of 2025 reached $5.065 billion, indicating a 20.3% growth compared to Q3 2024. While we acknowledge the potential of Boston Scientific Corporation (NYSE:BSX) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we covered Boston Scientific Corporation (NYSE:BSX) and shared the list of best healthcare AI stocks to buy. In its Q3 2025 investor letter, Baron Health Care Fund noted that, Boston Scientific Corporation (NYSE:BSX) declined in the quarter due to rising competition. In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.